ClinConnect ClinConnect Logo
Search / Trial NCT00372008

Pharmacokinetics of Testosterone Lotion in the Treatment of Hypogonadal Males

Launched by ACRUX DDS PTY LTD · Sep 5, 2006

Trial Information

Current as of July 22, 2025

Completed

Keywords

ClinConnect Summary

No description provided

Gender

MALE

Eligibility criteria

  • Inclusion Criteria:
  • Hypogonadal males between 18-70 years old with qualifying general medical health
  • Exclusion Criteria:
  • Disqualifying concurrent conditions or allergy/sensitivity to testosterone replacement therapy

About Acrux Dds Pty Ltd

Acrux DDS Pty Ltd is an innovative pharmaceutical company specializing in the development of advanced drug delivery systems. With a strong focus on improving patient outcomes, Acrux leverages its proprietary technology to create enhanced formulations for a range of therapeutic areas, including hormonal therapies and vaccines. The company is committed to rigorous clinical research and development processes, ensuring the safety and efficacy of its products. Acrux's vision is to transform healthcare through cutting-edge solutions that optimize medication adherence and effectiveness.

Locations

San Antonio, Texas, United States

Shreveport, Louisiana, United States

Torrance, California, United States

New Britain, Connecticut, United States

La Mesa, California, United States

Shreveport, Louisiana, United States

Ocala, Florida, United States

Birmingham, Alabama, United States

Patients applied

0 patients applied

Trial Officials

Tina Soulis, PhD

Study Director

Acrux Ltd

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials